This Study Tests the Effect of Risankizumab on the Metabolism in the Liver of Five Additional Drugs to Study Possible Drug Interactions in Patients With Psoriasis With or Without Psoriatic Arthritis
- Conditions
- Psoriasis
- Interventions
- First Posted Date
- 2016-05-13
- Last Posted Date
- 2017-09-25
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 21
- Registration Number
- NCT02772601
- Locations
- 🇩🇪
Boehringer Ingelheim Investigational Site, Berlin, Germany
Dose Finding, Efficacy and Safety of BI 655064 in Patients With Active Lupus Nephritis
- Conditions
- Lupus Nephritis
- Interventions
- Drug: BI 655064 dose 1Drug: BI 655064 dose 2Drug: BI 655064 dose 3Drug: Placebo
- First Posted Date
- 2016-05-12
- Last Posted Date
- 2021-07-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 121
- Registration Number
- NCT02770170
- Locations
- 🇺🇸
Feinstein Institute for Medical Research, Manhasset, New York, United States
🇵🇹Hospital Curry Cabral, EPE, Lisboa, Portugal
🇷🇸Institute of Rheumatology, Belgrade, Belgrade, Serbia
Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory CLL Patients Who Have Been Pre-treated With at Least One Prior Line of Systemic Therapy, and Who Are Eligible for Treatment With Ibrutinib
- Conditions
- Leukemia, Lymphocytic, Chronic, B-Cell
- Interventions
- First Posted Date
- 2016-05-03
- Last Posted Date
- 2020-09-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 7
- Registration Number
- NCT02759016
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Oregon Health and Sciences University, Portland, Oregon, United States
🇺🇸City of Hope, Duarte, California, United States
Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Linagliptin Compared With the Free Combination of Empagliflozin Tablet and Linagliptin Tablet in Healthy Male and Female Subjects
- First Posted Date
- 2016-05-02
- Last Posted Date
- 2017-11-22
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 56
- Registration Number
- NCT02758171
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
fMRI in Impulsivity
- Conditions
- Impulse Control DisordersBorderline Personality Disorder
- Interventions
- Behavioral: Experimental
- First Posted Date
- 2016-04-28
- Last Posted Date
- 2018-08-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 48
- Registration Number
- NCT02755181
- Locations
- 🇺🇸
Virginia Commonwealth University, Richmond, Virginia, United States
Investigation of the Effect of Nintedanib on the Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Patients With Non-small Cell Lung Cancer
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Drug: Microgynon
- First Posted Date
- 2016-04-26
- Last Posted Date
- 2019-03-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 2
- Registration Number
- NCT02751385
- Locations
- 🇩🇪
Klinikum Chemnitz gGmbH, Chemnitz, Germany
Real World Data on Gi(l)Otrif® Dose Adjustment
- Conditions
- Carcinoma, Non-Small-Cell Lung
- First Posted Date
- 2016-04-26
- Last Posted Date
- 2019-08-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 228
- Registration Number
- NCT02751879
- Locations
- 🇦🇹
SMZ Baumgartner Hoehe Otto Wagner Spital, Wien, Austria
🇨🇦BC Cancer Agency - Vancouver, Vancouver, British Columbia, Canada
🇯🇵Kurashiki Central Hospital, Okayama, Kurashiki, Japan
Safety and Effect on Central Retinal Thickness of BI 1026706 in Patients With Diabetic Macular Edema
- First Posted Date
- 2016-04-11
- Last Posted Date
- 2019-03-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 105
- Registration Number
- NCT02732951
- Locations
- 🇪🇸
Hospital Vall d'Hebron, Barcelona, Spain
🇵🇹Hospital de Vila Franca de Xira, Vila Franca de Xira, Portugal
🇫🇷HOP Lariboisière, Paris, France
To Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1467335 Following Multiple Dose Administration Over 28 Days
- First Posted Date
- 2016-04-11
- Last Posted Date
- 2021-06-07
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 36
- Registration Number
- NCT02733627
- Locations
- 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany
Olmutinib (BI 1482694) ADME Study
- Conditions
- Healthy
- Interventions
- Drug: [14C]BI 1482694
- First Posted Date
- 2016-03-29
- Last Posted Date
- 2016-07-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 8
- Registration Number
- NCT02722161
- Locations
- 🇳🇱
1370.7.31001 Boehringer Ingelheim Investigational Site, Zuidlaren, Netherlands